CytoDyn Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
CytoDyn Inc. (CYDY) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $3.87 million as of 2016-05-31, per its 10-K filed 2016-07-19.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2016-07-19
- 2016-05-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.87M.
- 2015-05-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.07M.
- 2014-05-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.89M.
- 2013-05-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.93M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2016-05-31 | $3.87M 10-K · filed 2016-07-19 |
| 2015-05-31 | $3.07M 10-K · filed 2016-07-19 |
| 2014-05-31 | $2.89M 10-K · filed 2015-07-10 |
| 2013-05-31 | $2.93M 10-K · filed 2014-07-10 |
| 2012-05-31 | $2.09M 10-K · filed 2013-08-29 |